Shanghai Escugen, a biopharmaceutical company based in China, has announced the dosing of the first patient in a Phase III clinical study for its candidate drug ESG401. The study is assessing the efficacy of ESG401 in patients with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) locally advanced or metastatic breast cancer, who have previously received at least first-line systematic chemotherapy.
ESG401 is an antibody-drug conjugate (ADC) that targets Trop-2, a protein overexpressed in various solid tumors. The drug is designed with an innovative and stable degradable linker, which significantly reduces off-target toxicity. Clinical data from existing studies indicate that ESG401 has a higher tolerated dose compared to other ADCs with the same target, and it exhibits a low incidence of both off-target and on-target toxicity, which is mild in nature. This highlights the significant safety advantages of ESG401.- Flcube.com
